IDSA Home

What's New

COVID-19 Treatment & Management Guidelines Feedback Survey

IDSA is interested in hearing from you! We have developed a survey to assist us in the future development of the IDSA Guidelines on the Treatment and Management of COVID-19. Your responses will be helpful as we strive to update and put forth new information. Thank you for providing your feedback!

IDSA and HIVMA Call for Greater U.S. Leadership in Accelerating Global Vaccine Equity

IDSA and its HIVMA support the Biden Administration’s call for new global commitments to control the COVID-19 pandemic and applaud the Administration’s initial steps of donating vaccine doses and making financial contributions to COVAX, the COVID-19 Vaccines Global Access initiative.

IDSA Guidelines on the Treatment and Management of Patients with COVID-19

Summarized here are the recommendations with comments related to the clinical practice guideline for the treatment and management of COVID-19. On September 21, 2021, IDSA released a new recommendation on the use of sarilumab; this update has been endorsed by SHEA, PIDS, and SIDP.

IDSA Response to Federal Response to Antimicrobial Resistance

IDSA is encouraged by today’s announcement from the Biden Administration on the allocation of more than $2 billion of American Rescue Plan funds to support infection prevention and efforts to combat antimicrobial resistance.

IDSA Submits Comments on Joint Commission’s Antibiotic Stewardship Requirements

IDSA has expressed support for several proposed revisions to The Joint Commission’s antibiotic stewardship requirements for hospitals, while also providing additional recommendations to ensure the changes align with the Society’s strategic priorities.

IDSA Comments on Medicare Physician Fee Schedule

IDSA submits comments to CMS advocating for better pay for ID physicians and provides comments on the Quality Payment Program and other issues of importance to ID physicians.